Chronogen finalizes licensing deal with McGill

Montreal-based Chronogen Inc has secured an exclusive worldwide licence from McGill Univ for screening assays for targets and drugs used in the treatment and prevention of lipid disorder linked to atherosclerosis. The licensed technology, which expands Chronogen’s IP portfolio in the field of aging and age-related diseases, is based on discoveries made by Dr Siegfried Hekimi, founder and chief scientific officer of Chronogen and a biology professor at McGill. Chronogen and McGill also concluded a multi-million dollar research collaboration to develop pre-clinical models that will guide the selection of clinical indications for new drug candidates. Chronogen has a first option to future IP rights and novel biological models and reagents created in the Hekimi laboratory.